Clarity Pharmaceuticals (ASX: CU6) — Company Overview, News & Financial Data
Clarity Pharmaceuticals develops theranostic radiopharmaceuticals for cancer diagnosis and treatment.
Clarity Pharmaceuticals
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation theranostic products to address the treatment and diagnosis of cancer. The company utilizes its proprietary SAR Technology platform, which binds targeted delivery molecules to copper isotopes, including copper-64 for imaging and copper-67 for therapy. Its drug pipeline targets major oncology indications such as prostate cancer, breast cancer, and neuroendocrine tumors. Key clinical programs include SAR-bisPSMA for prostate cancer diagnosis and therapy, SARTATE for neuroendocrine tumors, and SAR-Bombesin for targeted prostate cancer imaging, aiming to improve targeted cancer therapies and overcome supply chain challenges.
Snapshot
Operations
Products and/or services of Clarity Pharmaceuticals
- Prostate cancer theranostic development: The company advances its dual-targeted PSMA radiopharmaceutical candidate for identifying and treating prostate cancer, conducting clinical trials evaluating copper-64 for positron emission tomography diagnostic imaging and copper-67 for targeted beta radionuclide therapy.
- Targeted diagnostic imaging agents: The organization develops radiopharmaceutical diagnostic agents using copper-64 isotopes coupled with proprietary chelating technology, conducting clinical studies to detect primary, recurrent, and metastatic prostate cancer lesions using standard PET scanning equipment.
- Targeted therapeutic radiopharmaceuticals: The entity evaluates copper-67 radioisotope therapeutic compounds designed to deliver localized radiation directly to cancer cells expressing targeted surface receptors, focusing on advanced prostate cancer patients who have failed prior standard treatments.
- Bombesin receptor targeted radiotherapeutics: The business develops targeted radiopharmaceutical agents designed to bind gastrin-releasing peptide receptors, conducting clinical evaluation for imaging and treating prostate cancer patients whose disease expresses low or negative prostate-specific membrane antigen expression.
- Somatostatin receptor targeted theranostics: The company researches chelator-paired radioisotopes targeting somatostatin receptor subtype 2, evaluating diagnostic imaging and therapeutic efficacy in clinical trials for adult and pediatric patients diagnosed with neuroendocrine tumors and neuroblastoma.
- Bifunctional chelator technology platform: The platform utilizes proprietary macrocyclic cage structures to securely bind copper isotopes to targeted delivery molecules, preventing isotope leakage in vivo and enabling centralized manufacturing with extended shelf life for global distribution.
Clarity Pharmaceuticals executive team
- Dr. Alan John Taylor Ph.D.Executive Chairman
- Ms. Michelle ParkerCEO, MD & Executive Director
- Mr. David K. Green BEc., CAChief Financial Officer
- Dr. Colin David Biggin Ph.D.COO & Non-Independent Executive Director
- Dr. Matthew Harris BSc., M.B.A., Ph.D.Chief Scientific Officer
- Ms. Lisa SadetskayaDirector of Corporate Communications.
- Ms. Mary BennettHead of People & Culture
- Mr. Shaemus GleasonExecutive Vice President of Operations
- Dr. Othon GervasioChief Medical Officer
- Ms. Eva LengyelovaExecutive Vice President of Clinical Development